Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease - PubMed (original) (raw)

Comparative Study

doi: 10.1007/BF00920240.

Affiliations

Comparative Study

Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease

B Heilig et al. J Clin Immunol. 1993 Sep.

Abstract

Two TNF binding proteins have been characterized as soluble fragments of TNF receptors. We measured the plasma concentrations of soluble type A (p75) and type B (p55) TNF receptors in patients with systemic lupus erythematodes (SLE), progressive systemic sclerosis (PSS), and mixed connective tissue disease (MCTD). In SLE and PSS patients plasma concentrations of both types of TNF receptors and in MCTD patients type A TNF receptors were significantly elevated compared to controls. Plasma concentrations of both soluble TNF receptors were highly correlated in SLE, PSS, and MCTD patients, indicating a possible coregulation of both TNF receptors. In contrast, soluble interleukin 2 receptor (sCD 25) plasma concentrations were not correlated and seem to be an independent parameter. The soluble forms of the TNF receptors neutralize TNF in cytotoxicity assays and are functionally active as TNF antagonists. In one patient with SLE, autoantibodies against type A TNF receptors were detected, TNF alpha, and TNF beta did not interfere with the autoantibody binding to the receptor.

PubMed Disclaimer

References

    1. J Clin Immunol. 1988 Nov;8(6):447-52 - PubMed
    1. J Biol Chem. 1989 Sep 5;264(25):14927-34 - PubMed
    1. J Immunol Methods. 1991 Sep 20;143(1):127-36 - PubMed
    1. Cell. 1990 Apr 20;61(2):361-70 - PubMed
    1. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5233-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources